Literature DB >> 28409615

Peritonsillar Abscess.

Nicholas J Galioto1.   

Abstract

Peritonsillar abscess is the most common deep infection of the head and neck, occurring primarily in young adults. Diagnosis is usually made on the basis of clinical presentation and examination. Symptoms and findings generally include fever, sore throat, dysphagia, trismus, and a "hot potato" voice. Drainage of the abscess, antibiotic therapy, and supportive therapy for maintaining hydration and pain control are the cornerstones of treatment. Most patients can be managed in the outpatient setting. Peritonsillar abscesses are polymicrobial infections, and antibiotics effective against group A streptococcus and oral anaerobes should be first-line therapy. Corticosteroids may be helpful in reducing symptoms and speeding recovery. Promptly recognizing the infection and initiating therapy are important to avoid potentially serious complications, such as airway obstruction, aspiration, or extension of infection into deep neck tissues. Patients with peritonsillar abscess are usually first encountered in the primary care outpatient setting or in the emergency department. Family physicians with appropriate training and experience can diagnose and treat most patients with peritonsillar abscess.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28409615

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  12 in total

1.  Oral and Maxillofacial Infections-A Bacterial and Clinical Cross-Section.

Authors:  Bartłomiej Kamiński; Katarzyna Błochowiak; Konrad Kołomański; Maciej Sikora; Sławomir Karwan; Dariusz Chlubek
Journal:  J Clin Med       Date:  2022-05-12       Impact factor: 4.964

2.  Ageusia: A Symptom of Peritonsillar Abscess?

Authors:  K Revathishree; S Shyam Sudhakar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-03-10

3.  The effectiveness of transcutaneous cervical ultrasonography for diagnosing peritonsillar abscess in a patient complaining of sore throat.

Authors:  Hiroshi Hori; Takahiko Fukuchi; Hitoshi Sugawara
Journal:  J Gen Fam Med       Date:  2020-08-27

Review 4.  Ubi pus, ibi evacua: a review of 601 peritonsillar abscess adult cases.

Authors:  Giorgos Sideris; Vangelis Malamas; George Tyrellis; Pavlos Maragkoudakis; Alexander Delides; Thomas Nikolopoulos
Journal:  Ir J Med Sci       Date:  2021-10-06       Impact factor: 2.089

5.  Concurrent Peritonsillar Abscess and Uvular Hydrops in a Pediatric Patient.

Authors:  Rissa A Zudekoff; Maria F Pugliese; Merlin C Lowe
Journal:  Cureus       Date:  2022-01-28

6.  Recurrent Peritonsillar Abscess in Post-tonsillectomy Patient.

Authors:  Jacqueline Mirza; Skyler Coetzee; Miguel Belaunzaran; Robert W Trenschel; Tatyana Borisiak
Journal:  Cureus       Date:  2022-02-16

7.  Analysis of Smoking Behavior in Patients With Peritonsillar Abscess: A Rural Community Hospital's Experience.

Authors:  Chelsea Clark; Anthony Santarelli; Stefan Merrill; John Ashurst
Journal:  Cureus       Date:  2022-03-18

8.  Fulminating deep tissue space infection with Streptococcus constellatus presenting initially as a sore throat.

Authors:  Joe Glover; Gorana Kovacevic; Gary Walton; David Parr
Journal:  BMJ Case Rep       Date:  2020-03-31

9.  High Risk of Peritonsillar Abscess in End-Stage Renal Disease Patients: A Nationwide Real-World Cohort Study.

Authors:  Geng-He Chang; Ang Lu; Yao-Hsu Yang; Chia-Yen Liu; Pey-Jium Chang; Chuan-Pin Lee; Yao-Te Tsai; Cheng-Ming Hsu; Ching-Yuan Wu; Wei-Tai Shih; Ming-Shao Tsai
Journal:  Int J Environ Res Public Health       Date:  2021-06-24       Impact factor: 3.390

Review 10.  A Review of Evidence-Based Recommendations for Pericoronitis Management and a Systematic Review of Antibiotic Prescribing for Pericoronitis among Dentists: Inappropriate Pericoronitis Treatment Is a Critical Factor of Antibiotic Overuse in Dentistry.

Authors:  Jan Schmidt; Martina Kunderova; Nela Pilbauerova; Martin Kapitan
Journal:  Int J Environ Res Public Health       Date:  2021-06-24       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.